Melacine Relapse-Free Survival Endpoint Could Give Inconclusive Result

Use of relapse-free survival as a primary endpoint in studies of Corixa's melanoma vaccine Melacine would produce an ambiguous efficacy result, FDA's Oncologic Drugs Advisory Committee suggested